Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
N-acetylglutamate kinase (NAGK) is an enzyme that catalyzes the phosphorylation of N-acetylglutamate (NAG) using ATP, producing N-acetylglutamyl phosphate. This reaction is the second step in the arginine biosynthesis pathway in microorganisms and plants. The enzyme's activity is regulated by feedback inhibition by arginine; when arginine levels are high, NAGK is inhibited to reduce arginine synthesis[6][3][4]. Structurally, NAGK forms ring-like oligomeric assemblies (often hexamers or tetramers) with distinct N- and C-terminal domains where the active sites for NAG and ATP are located[4]. There are no direct human diseases associated with NAGK deficiency, as animals do not possess this enzyme in their urea cycle; the human urea cycle uses N-acetylglutamate synthase (NAGS) instead[5]. However, in bacteria and plants, NAGK is essential for de novo arginine production[6][3]. If you need further details or structured information, specialized databases such as UniProt or BRENDA will provide in-depth molecular and regulatory annotations on N-acetylglutamate kinase.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on N-acetylglutamate kinase (NAGK).